Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Terkeltaub, Robert Dr.

    TitleProfessor
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9500 Gilman Drive #9111-K
    CA La Jolla 92093
    Phone858-552-8585
    vCardDownload vCard

      Collapse Research 
      Collapse Research Activities and Funding
      Rheumatic Diseases Research Training Grant
      NIH/NIAMS T32AR064194May 9, 2013 - Apr 30, 2018
      Role: Principal Investigator
      Innate Inflammation in Osteoarthritis
      VA I01BX001660Apr 1, 2012 - Mar 31, 2021
      Role: Principal Investigator
      Transglutaminase 2 in Arterial Calcification and Atherosclerosis
      NIH/NHLBI R01HL087252May 15, 2008 - Dec 31, 2012
      Role: Principal Investigator
      Chondrocyte S100/Calgranulins and RAGE in Osteoarthritis
      NIH/NIAMS R01AR054135Jun 1, 2006 - May 31, 2010
      Role: Principal Investigator
      ANK and Joint Ankylosis in Spondylitis
      NIH/NIAMS R01AR049366Jan 1, 2005 - Nov 30, 2008
      Role: Principal Investigator
      Molecular Mechanisms in Arterial Calcification
      NIH/NHLBI R01HL077360Jul 1, 2004 - Jun 30, 2014
      Role: Principal Investigator
      PTHRP 1 to 173 IN CHONDROCYTES
      NIH/NIAMS R01AR047347Apr 6, 2001 - Jan 31, 2006
      Role: Principal Investigator
      MULTIPURPOSE ARTHRITIS &MUSCULOSKELETAL DISEASE CENTER
      NIH/NIAMS P60AR040770Aug 1, 1991 - Feb 28, 2002
      Role: Co-Investigator
      Studies of Joint Aging and Osteoarthritis
      NIH P01AG007996Dec 1, 1988 - Apr 30, 2017
      Role: Co-Investigator
      LOW DENSITY LIPOPROTEIN AND INFLAMMATION
      NIH/NIDDK R01DK036702Jul 1, 1985 - Jun 30, 1996
      Role: Principal Investigator
      LOW DENSITY LIPOPROTEINS AND GOUT
      NIH/NIADDK R23AM036702Jul 1, 1985 - Jun 30, 1988
      Role: Principal Investigator
      LOW DENSITY LIPOPROTEINS AND GOUT
      NIH/NIDDK R23DK036702Jul 1, 1985 - Jun 30, 1988
      Role: Principal Investigator

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Terkeltaub R. What makes gouty inflammation so variable? BMC Med. 2017 Aug 18; 15(1):158. PMID: 28818081.
        View in: PubMed
      2. Dalbeth N, Bardin T, Doherty M, Lioté F, Richette P, Saag KG, So AK, Stamp LK, Choi HK, Terkeltaub R. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol. 2017 Sep; 13(9):561-568. PMID: 28794514.
        View in: PubMed
      3. Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Adler S, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis Rheumatol. 2017 Sep; 69(9):1903-1913. PMID: 28597604.
        View in: PubMed
      4. Terkeltaub R. Emerging uricosurics for gout. Expert Rev Clin Pharmacol. 2017 Mar; 10(3):247-249. PMID: 27937050.
        View in: PubMed
      5. Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet JL, Yeh LT, Terkeltaub R, Quart B. Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016 Oct 12; 18(1):236. PMID: 27733209.
        View in: PubMed
      6. Miner J, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet JL, Yeh LT, Terkeltaub R, Quart B. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016 Oct 03; 18(1):214. PMID: 27716403.
        View in: PubMed
      7. Lu N, Rai SK, Terkeltaub R, Kim SC, Menendez ME, Choi HK. Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States. Semin Arthritis Rheum. 2016 Oct; 46(2):253-8. PMID: 27217070; PMCID: PMC5035554 [Available on 10/01/17].
      8. Wang Y, Zhao X, Lotz M, Terkeltaub R, Liu-Bryan R. Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor ? coactivator 1a. Arthritis Rheumatol. 2015 May; 67(8):2141-53. PMID: 25940958; PMCID: PMC4519411.
      9. Zhao X, Petursson F, Viollet B, Lotz M, Terkeltaub R, Liu-Bryan R. Peroxisome proliferator-activated receptor ? coactivator 1a and FoxO3A mediate chondroprotection by AMP-activated protein kinase. Arthritis Rheumatol. 2014 Nov; 66(11):3073-82. PMID: 25047750; PMCID: PMC4343036.
      10. Wang Y, Viollet B, Terkeltaub R, Liu-Bryan R. AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. Ann Rheum Dis. 2016 Jan; 75(1):286-94. PMID: 25362043.
        View in: PubMed
      11. Liu-Bryan R, Terkeltaub R. Emerging regulators of the inflammatory process in osteoarthritis. Nat Rev Rheumatol. 2015 Jan; 11(1):35-44. PMID: 25266449; PMCID: PMC4374654.
      12. Terkeltaub R. Apolipoprotein a-I at the interface of vascular inflammation and arthritis. Arterioscler Thromb Vasc Biol. 2014 Mar; 34(3):474-6. PMID: 24554604; PMCID: PMC3975075.
      13. Khanna PP, Gladue HS, Singh MK, FitzGerald JD, Bae S, Prakash S, Kaldas M, Gogia M, Berrocal V, Townsend W, Terkeltaub R, Khanna D. Treatment of acute gout: a systematic review. Semin Arthritis Rheum. 2014 Aug; 44(1):31-8. PMID: 24650777.
        View in: PubMed
      14. Serrano RL, Yu W, Terkeltaub R. Mono-allelic and bi-allelic ENPP1 deficiency promote post-injury neointimal hyperplasia associated with increased C/EBP homologous protein expression. Atherosclerosis. 2014 Apr; 233(2):493-502. PMID: 24530784; PMCID: PMC4386864.
      15. Terkeltaub R. Gout: multinational gout guidelines: how do we move beyond 'déjà vu'? Nat Rev Rheumatol. 2013 Oct; 9(10):567-9. PMID: 24045709.
        View in: PubMed
      16. Petursson F, Husa M, June R, Lotz M, Terkeltaub R, Liu-Bryan R. Linked decreases in liver kinase B1 and AMP-activated protein kinase activity modulate matrix catabolic responses to biomechanical injury in chondrocytes. Arthritis Res Ther. 2013 Jul 25; 15(4):R77. PMID: 23883619; PMCID: PMC3979085.
      17. Terkeltaub R. Are cherries now ripe for use as a complementary therapeutic in gout? Appraisal of the state of evidence. Evid Based Med. 2013 Dec; 18(6):230-1. PMID: 23416419.
        View in: PubMed
      18. Prowse RL, Dalbeth N, Kavanaugh A, Adebajo AO, Gaffo AL, Terkeltaub R, Mandell BF, Suryana BP, Goldenstein-Schainberg C, Diaz-Torne C, Khanna D, Lioté F, Mccarthy G, Kerr GS, Yamanaka H, Janssens H, Baraf HF, Chen JH, Vazquez-Mellado J, Harrold LR, Stamp LK, Van De Laar MA, Janssen M, Doherty M, Boers M, Edwards NL, Gow P, Chapman P, Khanna P, Helliwell PS, Grainger R, Schumacher HR, Neogi T, Jansen TL, Louthrenoo W, Sivera F, Taylor WJ, Alten R. A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol. 2013 Apr; 40(4):498-505. PMID: 23418379.
        View in: PubMed
      19. Terkeltaub R, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, King-Davis S, Weinstein SP. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther. 2013 Feb 01; 15(1):R25. PMID: 23375025; PMCID: PMC3672764.
      20. Husa M, Petursson F, Lotz M, Terkeltaub R, Liu-Bryan R. C/EBP homologous protein drives pro-catabolic responses in chondrocytes. Arthritis Res Ther. 2013; 15(6):R218. PMID: 24351550; PMCID: PMC3978428.
      21. Terkeltaub R. Imaging joints for calcium pyrophosphate crystal deposition: a knock to the knees. Arthritis Res Ther. 2012 Dec 27; 14(6):128. PMID: 23270654; PMCID: PMC3674586.
      22. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct; 64(10):1431-46. PMID: 23024028; PMCID: PMC3683400.
      23. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012 Oct; 64(10):1447-61. PMID: 23024029; PMCID: PMC3662546.
      24. Schumacher HR, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP, Yancopoulos GD, Wang J, Terkeltaub R. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken). 2012 Oct; 64(10):1462-70. PMID: 22549879.
        View in: PubMed
      25. Liu-Bryan R, Terkeltaub R. The growing array of innate inflammatory ignition switches in osteoarthritis. Arthritis Rheum. 2012 Jul; 64(7):2055-8. PMID: 22488656; PMCID: PMC3711830.
      26. Dammanahalli KJ, Stevens S, Terkeltaub R. Vanin-1 pantetheinase drives smooth muscle cell activation in post-arterial injury neointimal hyperplasia. PLoS One. 2012; 7(6):e39106. PMID: 22720042; PMCID: PMC3374784.
      27. Yu W, Liu-Bryan R, Stevens S, Damanahalli JK, Terkeltaub R. RAGE signaling mediates post-injury arterial neointima formation by suppression of liver kinase B1 and AMPK activity. Atherosclerosis. 2012 Jun; 222(2):417-25. PMID: 22552116; PMCID: PMC3361645.
      28. Schumacher HR, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, Yancopoulos GD, Soo Y, King-Davis S, Weinstein SP, Radin AR. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012 Mar; 64(3):876-84. PMID: 22223180.
        View in: PubMed
      29. Neogi T, George J, Rekhraj S, Struthers AD, Choi H, Terkeltaub R. Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum. 2012 Feb; 64(2):327-38. PMID: 21953377; PMCID: PMC3265683.
      30. Nitschke Y, Baujat G, Botschen U, Wittkampf T, du Moulin M, Stella J, Le Merrer M, Guest G, Lambot K, Tazarourte-Pinturier MF, Chassaing N, Roche O, Feenstra I, Loechner K, Deshpande C, Garber SJ, Chikarmane R, Steinmann B, Shahinyan T, Martorell L, Davies J, Smith WE, Kahler SG, McCulloch M, Wraige E, Loidi L, Höhne W, Martin L, Hadj-Rabia S, Terkeltaub R, Rutsch F. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. Am J Hum Genet. 2012 Jan 13; 90(1):25-39. PMID: 22209248; PMCID: PMC3257960.
      31. Nitschke Y, Weissen-Plenz G, Terkeltaub R, Rutsch F. Npp1 promotes atherosclerosis in ApoE knockout mice. J Cell Mol Med. 2011 Nov; 15(11):2273-83. PMID: 21477221; PMCID: PMC3154990.
      32. Terkeltaub R, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011 Aug; 63(8):2226-37. PMID: 21480191.
        View in: PubMed
      33. Terkeltaub R, Yang B, Lotz M, Liu-Bryan R. Chondrocyte AMP-activated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin-1ß and tumor necrosis factor a. Arthritis Rheum. 2011 Jul; 63(7):1928-37. PMID: 21400477; PMCID: PMC3128233.
      34. Khanna D, Sarkin AJ, Khanna PP, Shieh MM, Kavanaugh AF, Terkeltaub R, Lee SJ, Singh JA, Hirsch JD. Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology (Oxford). 2011 Jul; 50(7):1331-6. PMID: 21372003; PMCID: PMC3307519.
      35. Cecil DL, Terkeltaub R. Arterial calcification is driven by RAGE in Enpp1-/- mice. J Vasc Res. 2011; 48(3):227-35. PMID: 21099228; PMCID: PMC2997448.
      36. Sarkin AJ, Levack AE, Shieh MM, Kavanaugh AF, Khanna D, Singh JA, Terkeltaub R, Lee SJ, Hirsch JD. Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment. J Eval Clin Pract. 2010 Dec; 16(6):1244-7. PMID: 20722884.
        View in: PubMed
      37. Lotz MK, Otsuki S, Grogan SP, Sah R, Terkeltaub R, D'Lima D. Cartilage cell clusters. Arthritis Rheum. 2010 Aug; 62(8):2206-18. PMID: 20506158; PMCID: PMC2921934.
      38. Liu-Bryan R, Terkeltaub R. Chondrocyte innate immune myeloid differentiation factor 88-dependent signaling drives procatabolic effects of the endogenous Toll-like receptor 2/Toll-like receptor 4 ligands low molecular weight hyaluronan and high mobility group box chromosomal protein 1 in mice. Arthritis Rheum. 2010 Jul; 62(7):2004-12. PMID: 20506365; PMCID: PMC2902571.
      39. Husa M, Liu-Bryan R, Terkeltaub R. Shifting HIFs in osteoarthritis. Nat Med. 2010 Jun; 16(6):641-4. PMID: 20526316; PMCID: PMC2917906.
      40. Terkeltaub R, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010 Apr; 62(4):1060-8. PMID: 20131255.
        View in: PubMed
      41. Hirsch JD, Terkeltaub R, Khanna D, Singh J, Sarkin A, Shieh M, Kavanaugh A, Lee SJ. Gout disease-specific quality of life and the association with gout characteristics. Patient Relat Outcome Meas. 2010 Mar 01; 2010:1-8. PMID: 21686040.
        View in: PubMed
      42. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010 Jan; 6(1):30-8. PMID: 20046204.
        View in: PubMed
      43. Polewski MD, Johnson KA, Foster M, Millán JL, Terkeltaub R. Inorganic pyrophosphatase induces type I collagen in osteoblasts. Bone. 2010 Jan; 46(1):81-90. PMID: 19733704; PMCID: PMC2818162.
      44. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, Wu R, Mellis S, Radin A. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009 Oct; 68(10):1613-7. PMID: 19635719; PMCID: PMC2732898.
      45. Terkeltaub R. Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res Ther. 2009; 11(4):236. PMID: 19664185; PMCID: PMC2745774.
      46. Terkeltaub R, Zelman D, Scavulli J, Perez-Ruiz F, Lioté F. Gout Study Group: update on hyperuricemia and gout. Joint Bone Spine. 2009 Jul; 76(4):444-6. PMID: 19559637.
        View in: PubMed
      47. Cecil DL, Appleton CT, Polewski MD, Mort JS, Schmidt AM, Bendele A, Beier F, Terkeltaub R. The pattern recognition receptor CD36 is a chondrocyte hypertrophy marker associated with suppression of catabolic responses and promotion of repair responses to inflammatory stimuli. J Immunol. 2009 Apr 15; 182(8):5024-31. PMID: 19342682; PMCID: PMC2698125.
      48. Terkeltaub R. A sugar transporter regulates serum urate levels: implications for prevention and management of hyperuricemia in gout. Curr Rheumatol Rep. 2009 Apr; 11(2):83-6. PMID: 19296879.
        View in: PubMed
      49. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009 Apr; 11(2):135-40. PMID: 19296886.
        View in: PubMed
      50. Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, Kavanaugh A. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009 May; 48(5):582-6. PMID: 19307257; PMCID: PMC2722803.
      51. Rutsch F, Böyer P, Nitschke Y, Ruf N, Lorenz-Depierieux B, Wittkampf T, Weissen-Plenz G, Fischer RJ, Mughal Z, Gregory JW, Davies JH, Loirat C, Strom TM, Schnabel D, Nürnberg P, Terkeltaub R. Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet. 2008 Dec; 1(2):133-40. PMID: 20016754; PMCID: PMC2794045.
      52. Terkeltaub R. Colchicine update: 2008. Semin Arthritis Rheum. 2009 Jun; 38(6):411-9. PMID: 18973929.
        View in: PubMed
      53. Hirsch JD, Lee SJ, Terkeltaub R, Khanna D, Singh J, Sarkin A, Harvey J, Kavanaugh A. Evaluation of an instrument assessing influence of Gout on health-related quality of life. J Rheumatol. 2008 Dec; 35(12):2406-14. PMID: 18925685.
        View in: PubMed
      54. Cecil DL, Terkeltaub R. Transamidation by transglutaminase 2 transforms S100A11 calgranulin into a procatabolic cytokine for chondrocytes. J Immunol. 2008 Jun 15; 180(12):8378-85. PMID: 18523305; PMCID: PMC2577366.
      55. Johnson KA, Rose DM, Terkeltaub R. Factor XIIIA mobilizes transglutaminase 2 to induce chondrocyte hypertrophic differentiation. J Cell Sci. 2008 Jul 01; 121(Pt 13):2256-64. PMID: 18544639; PMCID: PMC2615675.
      56. Johnson KA, Polewski M, Terkeltaub R. Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circ Res. 2008 Mar 14; 102(5):529-37. PMID: 18202319; PMCID: PMC2652242.
      57. Johnson KA, Yao W, Lane NE, Naquet P, Terkeltaub R. Vanin-1 pantetheinase drives increased chondrogenic potential of mesenchymal precursors in ank/ank mice. Am J Pathol. 2008 Feb; 172(2):440-53. PMID: 18187567; PMCID: PMC2312367.
      58. Terkeltaub R. Learning how and when to employ uricase as bridge therapy in refractory gout. J Rheumatol. 2007 Oct; 34(10):1955-8. PMID: 17924606.
        View in: PubMed
      59. Hough TA, Polewski M, Johnson K, Cheeseman M, Nolan PM, Vizor L, Rastan S, Boyde A, Pritzker K, Hunter AJ, Fisher EM, Terkeltaub R, Brown SD. Novel mouse model of autosomal semidominant adult hypophosphatasia has a splice site mutation in the tissue nonspecific alkaline phosphatase gene Akp2. J Bone Miner Res. 2007 Sep; 22(9):1397-407. PMID: 17539739.
        View in: PubMed
      60. Hennigan S, Terkeltaub R. Last call for alcohol in gout? Curr Rheumatol Rep. 2007 Jun; 9(3):229-30. PMID: 17531176.
        View in: PubMed
      61. Strnad P, Harada M, Siegel M, Terkeltaub R, Graham RM, Khosla C, Omary MB. Transglutaminase 2 regulates mallory body inclusion formation and injury-associated liver enlargement. Gastroenterology. 2007 Apr; 132(4):1515-26. PMID: 17408647.
        View in: PubMed
      62. Scott P, Ma H, Viriyakosol S, Terkeltaub R, Liu-Bryan R. Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol. 2006 Nov 01; 177(9):6370-8. PMID: 17056568.
        View in: PubMed
      63. Zhang Y, Terkeltaub R, Nevitt M, Xu L, Neogi T, Aliabadi P, Niu J, Felson DT. Lower prevalence of chondrocalcinosis in Chinese subjects in Beijing than in white subjects in the United States: the Beijing Osteoarthritis Study. Arthritis Rheum. 2006 Nov; 54(11):3508-12. PMID: 17075853.
        View in: PubMed
      64. Rose DM, Sydlaske AD, Agha-Babakhani A, Johnson K, Terkeltaub R. Transglutaminase 2 limits murine peritoneal acute gout-like inflammation by regulating macrophage clearance of apoptotic neutrophils. Arthritis Rheum. 2006 Oct; 54(10):3363-71. PMID: 17009310.
        View in: PubMed
      65. Harmey D, Johnson KA, Zelken J, Camacho NP, Hoylaerts MF, Noda M, Terkeltaub R, Millán JL. Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in Akp2(-/-) mice. J Bone Miner Res. 2006 Sep; 21(9):1377-86. PMID: 16939396.
        View in: PubMed
      66. Lee SJ, Terkeltaub R. New developments in clinically relevant mechanisms and treatment of hyperuricemia. Curr Rheumatol Rep. 2006 Jun; 8(3):224-30. PMID: 16901081.
        View in: PubMed
      67. Terkeltaub R. Physiologic and pathologic functions of the NPP nucleotide pyrophosphatase/phosphodiesterase family focusing on NPP1 in calcification. Purinergic Signal. 2006 Jun; 2(2):371-7. PMID: 18404477; PMCID: PMC2254483.
      68. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther. 2006; 8 Suppl 1:S3. PMID: 16820042; PMCID: PMC3226108.
      69. Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006; 8 Suppl 1:S4. PMID: 16820043; PMCID: PMC3226109.
      70. Boisvert WA, Rose DM, Johnson KA, Fuentes ME, Lira SA, Curtiss LK, Terkeltaub R. Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol. 2006 Apr; 168(4):1385-95. PMID: 16565511; PMCID: PMC1606562.
      71. Neogi T, Booth SL, Zhang YQ, Jacques PF, Terkeltaub R, Aliabadi P, Felson DT. Low vitamin K status is associated with osteoarthritis in the hand and knee. Arthritis Rheum. 2006 Apr; 54(4):1255-61. PMID: 16572460.
        View in: PubMed
      72. Lee SJ, Terkeltaub R, Kavanaugh A. Recent developments in diet and gout. Curr Opin Rheumatol. 2006 Mar; 18(2):193-8. PMID: 16462528.
        View in: PubMed
      73. Liu-Bryan R, Terkeltaub R. Evil humors take their toll as innate immunity makes gouty joints TREM-ble. Arthritis Rheum. 2006 Feb; 54(2):383-6. PMID: 16447213.
        View in: PubMed
      74. Terkeltaub R. Hyperuricemia treatment: is creatinine clearance a safer allopurinol dosing meter than plasma creatinine levels? Nat Clin Pract Rheumatol. 2006 Feb; 2(2):68-9. PMID: 16932657.
        View in: PubMed
      75. Terkeltaub R. Gout in 2006: the perfect storm. Bull NYU Hosp Jt Dis. 2006; 64(1-2):82-6. PMID: 17121496.
        View in: PubMed
      76. Cecil DL, Johnson K, Rediske J, Lotz M, Schmidt AM, Terkeltaub R. Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J Immunol. 2005 Dec 15; 175(12):8296-302. PMID: 16339570.
        View in: PubMed
      77. Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 2005 Sep; 52(9):2936-46. PMID: 16142712.
        View in: PubMed
      78. Wu CW, Terkeltaub R. What do epidemiologic studies tell us about hyperuricemia and cardiovascular disease and death? Curr Rheumatol Rep. 2005 Jun; 7(3):211-2. PMID: 15918997.
        View in: PubMed
      79. Wu CW, Terkeltaub R, Kalunian KC. Calcium-containing crystals and osteoarthritis: implications for the clinician. Curr Rheumatol Rep. 2005 Jun; 7(3):213-9. PMID: 15918998.
        View in: PubMed
      80. Anderson HC, Harmey D, Camacho NP, Garimella R, Sipe JB, Tague S, Bi X, Johnson K, Terkeltaub R, Millán JL. Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. Am J Pathol. 2005 Jun; 166(6):1711-20. PMID: 15920156; PMCID: PMC1602415.
      81. Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol. 2005 Apr 15; 174(8):5016-23. PMID: 15814732.
        View in: PubMed
      82. Zhang Y, Johnson K, Russell RG, Wordsworth BP, Carr AJ, Terkeltaub R, Brown MA. Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate. Arthritis Rheum. 2005 Apr; 52(4):1110-7. PMID: 15818664.
        View in: PubMed
      83. Rutsch F, Terkeltaub R. Deficiencies of physiologic calcification inhibitors and low-grade inflammation in arterial calcification: lessons for cartilage calcification. Joint Bone Spine. 2005 Mar; 72(2):110-8. PMID: 15797489.
        View in: PubMed
      84. Johnson KA, Terkeltaub R. External GTP-bound transglutaminase 2 is a molecular switch for chondrocyte hypertrophic differentiation and calcification. J Biol Chem. 2005 Apr 15; 280(15):15004-12. PMID: 15691824.
        View in: PubMed
      85. Dong H, Maddux BA, Altomonte J, Meseck M, Accili D, Terkeltaub R, Johnson K, Youngren JF, Goldfine ID. Increased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance. Diabetes. 2005 Feb; 54(2):367-72. PMID: 15677494.
        View in: PubMed
      86. Cecil DL, Rose DM, Terkeltaub R, Liu-Bryan R. Role of interleukin-8 in PiT-1 expression and CXCR1-mediated inorganic phosphate uptake in chondrocytes. Arthritis Rheum. 2005 Jan; 52(1):144-54. PMID: 15641067.
        View in: PubMed
      87. Johnson K, Terkeltaub R. Inorganic pyrophosphate (PPI) in pathologic calcification of articular cartilage. Front Biosci. 2005 Jan 01; 10:988-97. PMID: 15569637.
        View in: PubMed
      88. Ruf N, Uhlenberg B, Terkeltaub R, Nürnberg P, Rutsch F. The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI). Hum Mutat. 2005 Jan; 25(1):98. PMID: 15605415.
        View in: PubMed
      89. Johnson K, Polewski M, van Etten D, Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. Arterioscler Thromb Vasc Biol. 2005 Apr; 25(4):686-91. PMID: 15625282.
        View in: PubMed
      90. Bieber JD, Terkeltaub R. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. 2004 Aug; 50(8):2400-14. PMID: 15334451.
        View in: PubMed
      91. Tramontini N, Huber C, Liu-Bryan R, Terkeltaub R, Kilgore KS. Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis. Arthritis Rheum. 2004 Aug; 50(8):2633-9. PMID: 15334478.
        View in: PubMed
      92. Bieber J, Terkeltaub R. The role of hypertension in cyclosporine-induced hyperuricemia. Curr Rheumatol Rep. 2004 Jun; 6(3):215-6. PMID: 15134600.
        View in: PubMed
      93. Johnson K, Svensson CI, Etten DV, Ghosh SS, Murphy AN, Powell HC, Terkeltaub R. Mediation of spontaneous knee osteoarthritis by progressive chondrocyte ATP depletion in Hartley guinea pigs. Arthritis Rheum. 2004 Apr; 50(4):1216-25. PMID: 15077304.
        View in: PubMed
      94. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millán JL. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol. 2004 Apr; 164(4):1199-209. PMID: 15039209; PMCID: PMC1615351.
      95. Liu R, Lioté F, Rose DM, Merz D, Terkeltaub R. Proline-rich tyrosine kinase 2 and Src kinase signaling transduce monosodium urate crystal-induced nitric oxide production and matrix metalloproteinase 3 expression in chondrocytes. Arthritis Rheum. 2004 Jan; 50(1):247-58. PMID: 14730623.
        View in: PubMed
      96. Vaingankar SM, Fitzpatrick TA, Johnson K, Goding JW, Maurice M, Terkeltaub R. Subcellular targeting and function of osteoblast nucleotide pyrophosphatase phosphodiesterase 1. Am J Physiol Cell Physiol. 2004 May; 286(5):C1177-87. PMID: 15075217.
        View in: PubMed
      97. Schraufstatter IU, Trieu K, Zhao M, Rose DM, Terkeltaub R, Burger M. IL-8-mediated cell migration in endothelial cells depends on cathepsin B activity and transactivation of the epidermal growth factor receptor. J Immunol. 2003 Dec 15; 171(12):6714-22. PMID: 14662875.
        View in: PubMed
      98. Terkeltaub R. Questions & answers. What's the difference between gout and pseudogout? Health News. 2003 Dec; 9(12):16. PMID: 14679973.
        View in: PubMed
      99. Terkeltaub R. Clinical practice. Gout. N Engl J Med. 2003 Oct 23; 349(17):1647-55. PMID: 14573737.
        View in: PubMed
      100. Merz D, Liu R, Johnson K, Terkeltaub R. IL-8/CXCL8 and growth-related oncogene alpha/CXCL1 induce chondrocyte hypertrophic differentiation. J Immunol. 2003 Oct 15; 171(8):4406-15. PMID: 14530367.
        View in: PubMed
      101. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Höhne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A, McGill J, Filippone M, Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M, Terkeltaub R, Nürnberg P. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet. 2003 Aug; 34(4):379-81. PMID: 12881724.
        View in: PubMed
      102. Johnson K, Goding J, Van Etten D, Sali A, Hu SI, Farley D, Krug H, Hessle L, Millán JL, Terkeltaub R. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res. 2003 Jun; 18(6):994-1004. PMID: 12817751.
        View in: PubMed
      103. Pay S, Terkeltaub R. Calcium pyrophosphate dihydrate and hydroxyapatite crystal deposition in the joint: new developments relevant to the clinician. Curr Rheumatol Rep. 2003 Jun; 5(3):235-43. PMID: 12744817.
        View in: PubMed
      104. Johnson K, Farley D, Hu SI, Terkeltaub R. One of two chondrocyte-expressed isoforms of cartilage intermediate-layer protein functions as an insulin-like growth factor 1 antagonist. Arthritis Rheum. 2003 May; 48(5):1302-14. PMID: 12746903.
        View in: PubMed
      105. Rutsch F, Terkeltaub R. Parallels between arterial and cartilage calcification: what understanding artery calcification can teach us about chondrocalcinosis. Curr Opin Rheumatol. 2003 May; 15(3):302-10. PMID: 12707585.
        View in: PubMed
      106. Johnson KA, van Etten D, Nanda N, Graham RM, Terkeltaub R. Distinct transglutaminase 2-independent and transglutaminase 2-dependent pathways mediate articular chondrocyte hypertrophy. J Biol Chem. 2003 May 23; 278(21):18824-32. PMID: 12606540.
        View in: PubMed
      107. Bakre MM, Zhu Y, Yin H, Burton DW, Terkeltaub R, Deftos LJ, Varner JA. Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. Nat Med. 2002 Sep; 8(9):995-1003. PMID: 12185361.
        View in: PubMed
      108. Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, Terkeltaub R, Millan JL. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A. 2002 Jul 09; 99(14):9445-9. PMID: 12082181; PMCID: PMC123160.
      109. Terkeltaub R. Pseudogout, hypomagnesemia, and liver transplantation. Curr Rheumatol Rep. 2002 Jun; 4(3):243-4. PMID: 12010609.
        View in: PubMed
      110. Terkeltaub R, Johnson K, Murphy A, Ghosh S. Invited review: the mitochondrion in osteoarthritis. Mitochondrion. 2002 Feb; 1(4):301-19. PMID: 16120285.
        View in: PubMed
      111. Terkeltaub R. Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol. 2001 Jul; 281(1):C1-C11. PMID: 11401820.
        View in: PubMed
      112. Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol. 1998 Oct; 9(5):397-405. PMID: 9812193.
        View in: PubMed
      Robert's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department
      Physical Neighbors
      People whose addresses are nearby this person.
      _